Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 11 2024
0mins
Source: NASDAQ.COM
Overview of Invesco Biotechnology & Genome ETF (PBE): Launched in 2005, PBE is a smart beta ETF focused on the healthcare sector, aiming to outperform through non-cap weighted strategies based on various investment criteria. It has approximately $271.25 million in assets and an expense ratio of 0.58%.
Performance and Comparison: PBE has shown a return of about 30.14% over the past year with a high-risk profile, while investors may also consider traditional market cap weighted ETFs like IBB and XBI for lower costs and risks.
Analyst Views on PBE
Wall Street analysts forecast PBE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PBE is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 84.074
Low
Averages
High
Current: 84.074
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
